In a murine model, Ncom Gel markedly increased the percentage of CD80+ and CD86+ DCs in TDLNs, triggering an expansion of IFN-γ–producing CD8+ and CD4+ T cells and leading to a significant delay in tumor growth. This evidence concerns the gene CD86 and neoplasm.